{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Pelitrexol",
  "nciThesaurus": {
    "casRegistry": "446022-33-9",
    "chebiId": "",
    "chemicalFormula": "C20H25N5O6S",
    "definition": "A water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation",
    "fdaUniiCode": "DHT6E8M4KP",
    "identifier": "C2633",
    "preferredName": "Pelitrexol",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1556",
      "C2692"
    ],
    "synonyms": [
      "(2S)-2-(((5-(2-((6S)-2-Amino-4-oxo-1,4,5,6,7,8-hexahydropyrido(2,3-d)pyrimidin-6-yl)ethyl)-4-methylthiophen-2-yl)carbonyl)amino)pentanedioic Acid",
      "(2S)-2-[[[5-[2-[(6S)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl]carbonyl]amino]pentanedioic Acid",
      "AG2037",
      "PELITREXOL",
      "Pelitrexol"
    ]
  }
}